BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24595733)

  • 21. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.
    Suh KJ; Kim KH; Kim R; Byun JM; Kim M; Park JH; Keam B; Kim TM; Kim JS; Choi IS; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):894-901. PubMed ID: 29466847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of PET and PET/CT in managing the care of lymphoma patients.
    Evans WC; Gilmore D; English J
    J Nucl Med Technol; 2011 Sep; 39(3):190-4. PubMed ID: 21795369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?
    Nakamoto Y; Nogami M; Sugihara R; Sugimura K; Senda M; Togashi K
    Ann Nucl Med; 2011 Feb; 25(2):93-9. PubMed ID: 20957527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
    Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
    Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy.
    Zhang X; Fan W; Xia ZJ; Hu YY; Lin XP; Zhang YR; Li ZM; Liang PY; Li YH
    Chin J Cancer; 2015 Feb; 34(2):70-8. PubMed ID: 25418196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.
    Zhou Z; Chen C; Li X; Li Z; Zhang X; Chang Y; Lu L; Cui Y; Ma Y; Zhang M
    Ann Hematol; 2015 Jun; 94(6):963-7. PubMed ID: 25547320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.
    Kahn ST; Flowers C; Lechowicz MJ; Hollenbach K; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):961-5. PubMed ID: 17145526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
    Bruzzi JF; Macapinlac H; Tsimberidou AM; Truong MT; Keating MJ; Marom EM; Munden RF
    J Nucl Med; 2006 Aug; 47(8):1267-73. PubMed ID: 16883004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.
    El-Galaly TC; Mylam KJ; Brown P; Specht L; Christiansen I; Munksgaard L; Johnsen HE; Loft A; Bukh A; Iyer V; Nielsen AL; Hutchings M
    Haematologica; 2012 Jun; 97(6):931-6. PubMed ID: 22207683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
    Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
    Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.